US Patent

US10543192 — Glycopyrrolate salts

Formulation · Assigned to Dermira Inc · Expires 2033-02-28 · 7y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent discloses salts of glycopyrrolate, including solid forms and formulations such as topicals, and methods for making and using them.

USPTO Abstract

Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.

Drugs covered by this patent

glycopyrronium-tosylate (GLYCOPYRRONIUM TOSYLATE)

Patent Metadata

Patent number: US10543192
Jurisdiction: US
Classification: Formulation
Expires: 2033-02-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Dermira Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.